Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy

NCT00343759 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Lapatinib

Sponsor

University of Pennsylvania